The role of novel immunotherapies in non-Hodgkin lymphoma

Pishko, Allyson M.; Nasta, Sunita Dwivedy

doi:10.21037/tcr.2017.01.08

Cited by 30 publications

(36 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is necessary to develop clinical studies to develop new salvage therapy for pediatric patients with relapsed NHLs, especially for BL and LL. Recent multicenter clinical trials of therapies for adult patients with refractory NHL and leukemia showed that blinatumomab and chimeric antigen receptor T-cell therapy could be efficacious salvage therapies [28][29][30]. This is a possible candidate for salvage therapy in pediatric patients with relapsed and refractory NHL.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia

et al. 2020

View full text Add to dashboard Cite

Original ArticlePurpose The presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia. Materials and MethodsMedical records of 749 pediatric patients with NHL treated at participating institutions in mainland China, Japan, Korea, and Taiwan from January 2008 to December 2013 were reviewed. Demographic and clinical features, survival outcomes, and putative prognostic factors were analyzed. ResultsFive hundred thirty patients (71%) were male. The most common pathologic subtypes were Burkitt lymphoma (BL) (36%). Six hundred seven patients (81%) had advanced diseases at diagnosis. The 5-year overall survival and event-free survival (EFS) rates were 89% and 84%. The 5-year EFS rates of BL, lymphoblastic lymphoma, and diffuse large B-cell lymphoma were 88%, 88%, and 89%, and those of anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) were 71% and 56% (p < 0.001). Central nervous system involvement, high lactate dehydrogenase level (> 250 IU/mL), and advanced disease at diagnosis ( stage III) were associated with poor outcomes (p < 0.05). ALCL and PTCL relapsed more frequently than other pathologic subtypes (p < 0.001). ConclusionIn East Asia, PTCL was more frequent than in Western countries, and bone marrow involvement did not affect treatment outcome. This international study should motivate future collaborative study on NHL in East Asia.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In some cases, mABs are conjugated with radioisotopes or toxins to allow the specific delivery of these cytotoxic agents to the tumor cell target. In general, the mechanisms that allow therapeutic antibodies to inhibit growth or kill cancer cells fall into two categories: immune-mediated mechanisms as antibody-dependent cell cytotoxicity (ADCC), and complementary cytotoxicity (CDC), and mechanisms that interfere with tumorigenesis pathways (e.g., triggering apoptosis, inhibiting cell proliferation or blocking of angiogenesis) (25).…”

Section: Monoclonal Antibodies (Mabs)mentioning

confidence: 99%

“…The antibody was first approved in 1997 for NHL and subsequently, in 2009, for CLL. After that, rituximab has become an ordinary component of the treatment of FL, DLBCL, and MCL (25).…”

Section: Anti-cd Mabsmentioning

confidence: 99%

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

et al. 2019

View full text Add to dashboard Cite

The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) for targeted therapy in hematology. This review focuses on the efficacy results of the currently available targeted agents and recaps the main ongoing trials in the setting of mature B-Cell non-Hodgkin lymphomas. The objective is to summarize the different classes of novel agents approved for mature B-cell lymphomas, to describe in synoptic tables the results they achieved and, finally, to draw future scenarios as we glimpse through the ongoing clinical trials. Characteristics and therapeutic efficacy are summarized for the currently approved mAbs [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs i.e., inhibitors of B-cell receptor signaling, proteasome, mTOR BCL-2 HDAC pathways. The biological disease profiling of B-cell lymphoma subtypes may foster the discovery of innovative drug strategies for improving survival outcome in lymphoid neoplasms, as well as the trade-offs between efficacy and toxicity. The hope for clinical advantages should carefully be coupled with mindful awareness of the potential pitfalls and the occurrence of uneven, sometimes severe, toxicities.

show abstract

“…4785 In this issue of Clinical Cancer Research, Bacac and colleagues investigated the preclinical efficacy of a bispecific antibody in the treatment of lymphoma (1). To date, immunotherapy for the treatment of non-Hodgkin lymphoma (NHL) has been primarily focused on monoclonal antibody (mAb) therapy, which has demonstrated both single-agent activity and substantial synergy with cytotoxic chemotherapy (2). Further development of immunotherapy has been mixed.…”

mentioning

confidence: 99%